leadf
logo-loader
viewSUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals on hunt for complementary technologies and products to add to current programs

The company is considering acquiring or licensing life sciences technologies that it can add to its existing pipeline.

SUDA Pharmaceuticals Ltd - SUDA Pharmaceuticals on the prowl for new technologies and products to add to its current programs
It is looking for products that can be repurposed into oral sprays or products complementary to its portfolio of cancer and CNS treatments

SUDA Pharmaceuticals Ltd (ASX:SUD) (FRA:E4N) is committed to driving its current programs and sourcing new technologies and products.

As part of this process. the company is considering acquiring or licensing life sciences technologies that can be added to its existing pipeline.

It is specifically looking for products that it can repurpose into oral sprays or products that are complementary to its portfolio of cancer and central nervous system (CNS) treatments such as immune-oncology assets or medications for migraine and insomnia.

Chief executive officer Michael Baker said the company was on the look-out for deals globally, but with specific interest in the US, Europe and Australia, Acuris Mergermarket reports.

$3.5 million entitlement offer

The company launched a $3.5 million entitlement offer to existing shareholders, which closes on Thursday, after calling off a proposed licensing deal pertaining to a cancer therapy technology from a leading cancer research institute.

This transaction may have resulted in the ASX declining its readmission, resulting in SUDA deciding against proceeding with both the deal and the accompanying capital raising.

Baker said the $3.5 million funds raised in the entitlement offer to existing shareholders would go towards financing any potential deals, general working capital, as well as pay for the development of its existing pipeline.

This includes its anagrelide and the remaining OroMist assets.

Pipeline and new products

Given the decision not to move forward with the US oncology deal, SUDA has decided to continue to develop its existing technology in the oncology space.

It will also continue to progress its short-term insomnia treatment, ZolpiMist, for which the company this week received Therapeutics Goods Administration (TGA) approval for registration.

SUDA will continue to pursue the development of products together with partners Sanofi SA (NASDAQ:SNY) (EPA:SAN) Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) and Cann Pharmaceutical Australia.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.04 AUD

ASX:SUD
Market: ASX
Market Cap: $12.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead...

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a...

on 31/7/20

2 min read